EZH2 inactivating mutations have been reported in myeloid hemopathies including chronic myelomonocytic leukemia (CML), myelofibrosis, myelodysplastic syndrome (MDS) and AML [112,113,114]. Here, EZH2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.